MENA Biologics & Biosimilars Market is estimated to be valued at USD 549.3 Mn in 2026 and is expected to reach USD 752.5 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2026 to 2033.
There is stable growth in the biologics & biosimilars market in the MENA region, driven by the rising prevalence of chronic diseases, higher demand for advanced biologic medications, increased healthcare infrastructure development, and higher government initiatives toward providing affordable drug access. Investments have been made by different countries in the MENA region for the development of their healthcare infrastructure and local production of biopharmaceutical drugs, including biosimilars. Higher incidences of cancer, autoimmune diseases, kidney diseases, hemophilia, and ophthalmic diseases are contributing towards higher demand for biologics and biosimilars. In addition, there is also a requirement to control healthcare costs while sustaining efficacy, which is encouraging the use of biosimilars in the region.
By the Therapeutic Application, the Hemophilia segment is likely to have the biggest market share in 2026 because of increasing awareness, diagnosis rates, and availability of biologic replacement medicines. Programs of treatment, which are sponsored by the government, along with new long-acting biologics, improve outcomes and make treatment more accessible in the region.
By geography, the Gulf Cooperation Council (GCC) countries, namely Saudi Arabia and the United Arab Emirates, will dominate the MENA Biologics & Biosimilars market in 2026 because of high spending on healthcare, developed health infrastructure, favorable reimbursement policies, and growing investments in specialty pharma. On the other hand, North African countries, represented mainly by Egypt, will see the fastest growth because of increasing healthcare coverage, use of biosimilars, and investments in local pharma production.
Prominent Players in the MENA Biologics & Biosimilars Market
-
Pfizer Inc.
Company Overview
- Headquarters: New York, U.S.
- Establishment Year: 1849
- Employee Strength: Approximately 88,000 employees
- Leadership: Albert Bourla, Chairman & Chief Executive Officer
- Core Services/Products: Biosimilars, vaccines, oncology therapies, inflammation treatments, and specialty pharmaceuticals.
SWOT Analysis
- Strengths
- A strong biosimilar and biologics portfolio internationally.
- A large distribution network.
- Weaknesses
- The company’s reliance on its branded drugs.
- Risk from patents expiry cycles.
- Opportunities
- Biosimilar expansion across MENA countries.
- Increased demand for biologics that are cost-effective.
- Threats
- The risk of pricing pressures and regulatory problems.
- Competition from regional biosimilar manufacturers.
-
F. Hoffmann-La Roche Ltd
Company Overview
- Headquarters: Basel, Switzerland
- Establishment Year: 1896
- Employee Strength: Approximately 103,000 employees
- Leadership: Thomas Schinecker, Chief Executive Officer
- Core Services/Products: Oncology biologics, ophthalmology therapies, diagnostics, immunology products, and personalized healthcare solutions.
SWOT Analysis
- Strengths
- Leadership in biologics and oncology.
- Powerful research and development abilities.
- Weaknesses
- Dependence on high-end biologic drugs.
- High R&D expenditure.
